drugset / Trial / NCT01411280

Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)

NCT01411280

Phase 3 Completed 34 enrolled Temple University
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to assess whether methylphenidate is effective in enhancing the cognitive performance of children with the HbSS or HbSC genotype of SCD who have sustained neurological complications on laboratory-based measures of sustained attention, reaction time, and executive functions, and indirectly, verbal short-term and long-term memory.

Timeline

Start
2006-06
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 10 mg
Subject Methylphenidate Small molecule 20 mg

Indications